Form 4: Turn Therapeutics CFO Buys 2,500 Shares

Turn Therapeutics' Interim CFO, Zuraiz Chaudhary, purchased 2,500 shares of common stock at $3.50 per share, increasing direct beneficial ownership to 12,500 shares.

Summary

• Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer Zuraiz Chaudhary acquired 2,500 shares of Turn Therapeutics Inc. common stock.
• The transaction occurred on December 12, 2025, at a price of $3.50 per share.
• Following this purchase, Chaudhary directly beneficially owns 12,500 shares of the company's common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The insider purchase by a key financial officer is a positive signal, indicating confidence in the company's prospects. The Rule 10b5-1 plan suggests a pre-meditated investment.

Positives

• An insider purchase by a key financial officer (CFO) signals confidence in the company's future prospects.
• The acquisition increases the officer's direct beneficial ownership, aligning their interests further with shareholders.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned investment strategy rather than a reactive trade.

Negatives

• No specific negative points are directly discernible from this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain specific forward-looking statements or guidance, but an insider purchase can be interpreted as a positive signal regarding management's future expectations for the company.

Management Comments

• No direct quotes or paraphrased statements from company management are provided in this Form 4 filing, beyond the signature of the reporting person.

Industry Context

Insider purchases, particularly by high-ranking financial officers like the CFO, are often viewed by the market as a positive indicator of management's belief in the company's intrinsic value and future performance. This transaction aligns the CFO's personal financial interests with those of the shareholders, a common practice in corporate governance.

Comparison to Industry Standards

• Insider buying activity, especially by a CFO, is generally considered a positive signal across industries, suggesting management perceives the stock as undervalued or expects positive developments. While specific comparable companies or projects are not detailed in this filing, such an action is consistent with confident leadership in any sector.

Related Party Transactions

• The acquisition of common stock by an officer of the company (Zuraiz Chaudhary) is inherently a related party transaction.

Stakeholder Impact

• Shareholders: Potentially positive, as an insider purchase can boost investor confidence and signal management's belief in future stock appreciation.
• Employees: No direct impact mentioned, but a confident management team can indirectly foster a more stable work environment.

Next Steps

• This filing does not specify any future actions, events, or milestones.

Key Dates

Recommendation

The insider purchase by the Interim CFO, Zuraiz Chaudhary, is a positive indicator of management's confidence in Turn Therapeutics' future. This action aligns the executive's interests with shareholders and suggests a belief that the stock is a good value at the current price. However, without additional financial performance data or strategic updates, a 'hold' recommendation is prudent, acknowledging the positive signal while awaiting further fundamental catalysts.

Keywords

Turn Therapeutics, TTRX, Insider Trading, Form 4, Stock Purchase, CFO, Zuraiz Chaudhary, Equity Acquisition, Rule 10b5-1